Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer’s Disease Treatment
作者:Monika Schmidt、Ondrej Benek、Lucie Vinklarova、Martina Hrabinova、Lucie Zemanova、Matej Chribek、Vendula Kralova、Lukas Hroch、Rafael Dolezal、Antonin Lycka、Lukas Prchal、Daniel Jun、Laura Aitken、Frank Gunn-Moore、Kamil Kuca、Kamil Musilek
DOI:10.3390/ijms21062059
日期:——
compounds based on a benzothiazolyl scaffold and evaluated their inhibitory ability and mechanism of action. The most potent inhibitors contained 3-chloro and 4-hydroxy substitution on the phenyl ring moiety, a small substituent at position 6 on the benzothiazole moiety, and the two moieties were connected via a urea linker (4at, 4bb, and 4bg). These compounds exhibited IC50 values of 1–2 μM and showed an
人17β-羟类固醇脱氢酶10型是一种多功能蛋白,参与线粒体内的许多酶和结构过程。该酶被认为与几种神经系统疾病有关,例如智力低下,帕金森氏病或阿尔茨海默氏病,其中该酶与淀粉样β肽相互作用。我们基于苯并噻唑基支架制备了约60种新化合物,并评估了它们的抑制能力和作用机理。最有效的抑制剂在苯环部分包含3-氯和4-羟基取代基,在苯并噻唑部分的6位上具有小的取代基,并且两个部分通过脲连接基连接(4at,4bb和4bg)。这些化合物的IC50值为1-2μM,对底物乙酰乙酰辅酶A表现出无竞争性的作用机理。这些17β-羟基类固醇脱氢酶的非竞争性苯并噻唑基抑制剂是有希望用于神经退行性疾病潜在药物的化合物,值得进一步研究和开发。